Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation. (14th February 2011)
- Record Type:
- Journal Article
- Title:
- Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation. (14th February 2011)
- Main Title:
- Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation
- Authors:
- Pan, Min-Hsiung
Lin, Ying-Ting
Lin, Chih-Li
Wei, Chi-Shiang
Ho, Chi-Tang
Chen, Wei-Jen - Abstract:
- Abstract : Invasive breast cancer is the major cause of death among females and its incidence is closely linked to HER2 (human epidermal growth factor receptor 2) overexpression. Pterostilbene, a natural analog of resveratrol, exerts its cancer chemopreventive activity similar to resveratrol by inhibiting cancer cell proliferation and inducing apoptosis. However, the anti-invasive effect of pterostilbene on HER2-bearing breast cancer has not been evaluated. Here, we used heregulin- β 1 (HRG- β 1), a ligand for HER3, to transactivate HER2 signaling. We found that pterostilbene was able to suppress HRG- β 1-mediated cell invasion, motility and cell transformation of MCF-7 human breast carcinoma through down-regulation of matrix metalloproteinase-9 (MMP-9) activity and growth inhibition. In parallel, pterostilbene also inhibited protein and mRNA expression of MMP-9 driven by HRG- β 1, suggesting that pterostilbene decreased HRG- β 1-mediated MMP-9 induction via transcriptional regulation. Examining the signaling pathways responsible for HRG- β 1-associated MMP-9 induction and growth inhibition, we observed that pterostilbene, as well as SB203580 (p38 kinase inhibitor), can abolish the phosphorylation of p38 mitogen-activated protein kinase (p38 kinase), a downstream HRG- β 1-responsive kinase responsible for MMP-9 induction. In addition, HRG- β 1-driven Akt phosphorylation required for cell proliferation was also suppressed by pterostilbene. Taken together, our present resultsAbstract : Invasive breast cancer is the major cause of death among females and its incidence is closely linked to HER2 (human epidermal growth factor receptor 2) overexpression. Pterostilbene, a natural analog of resveratrol, exerts its cancer chemopreventive activity similar to resveratrol by inhibiting cancer cell proliferation and inducing apoptosis. However, the anti-invasive effect of pterostilbene on HER2-bearing breast cancer has not been evaluated. Here, we used heregulin- β 1 (HRG- β 1), a ligand for HER3, to transactivate HER2 signaling. We found that pterostilbene was able to suppress HRG- β 1-mediated cell invasion, motility and cell transformation of MCF-7 human breast carcinoma through down-regulation of matrix metalloproteinase-9 (MMP-9) activity and growth inhibition. In parallel, pterostilbene also inhibited protein and mRNA expression of MMP-9 driven by HRG- β 1, suggesting that pterostilbene decreased HRG- β 1-mediated MMP-9 induction via transcriptional regulation. Examining the signaling pathways responsible for HRG- β 1-associated MMP-9 induction and growth inhibition, we observed that pterostilbene, as well as SB203580 (p38 kinase inhibitor), can abolish the phosphorylation of p38 mitogen-activated protein kinase (p38 kinase), a downstream HRG- β 1-responsive kinase responsible for MMP-9 induction. In addition, HRG- β 1-driven Akt phosphorylation required for cell proliferation was also suppressed by pterostilbene. Taken together, our present results suggest that pterostilbene may serve as a chemopreventive agent to inhibit HRG- β 1/HER2-mediated aggressive and invasive phenotype of breast carcinoma through down-regulation of MMP-9, p38 kinase and Akt activation. … (more)
- Is Part Of:
- Evidence-based complementary and alternative medicine. Volume 2011(2011)
- Journal:
- Evidence-based complementary and alternative medicine
- Issue:
- Volume 2011(2011)
- Issue Display:
- Volume 2011, Issue 2011 (2011)
- Year:
- 2011
- Volume:
- 2011
- Issue:
- 2011
- Issue Sort Value:
- 2011-2011-2011-0000
- Page Start:
- Page End:
- Publication Date:
- 2011-02-14
- Subjects:
- Alternative medicine -- Periodicals
615.505 - Journal URLs:
- http://ecam.oupjournals.org ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/241/ ↗
http://www.hindawi.com/journals/ecam/ ↗ - DOI:
- 10.1093/ecam/nep093 ↗
- Languages:
- English
- ISSNs:
- 1741-427X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3831.036630
British Library HMNTS - ELD Digital store - Ingest File:
- 17437.xml